TYRA TYRA BIOSCIENCES, INC.
- 18.440
- -0.140-0.75%
- 18.440
- 0.0000.00%
TYRA BIOSCIENCES, INC. News
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Oppenheimer: Reiterated the Tyra Biosciences (TYRA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $28.00.
Oppenheimer: Reiterated the Tyra Biosciences (TYRA.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $25.00 to $28.00.
Oppenheimer Reiterates Outperform on Tyra Biosciences, Raises Price Target to $28
Oppenheimer analyst Matthew Biegler reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and raises the price target from $25 to $28.
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
Tyra Biosciences Price Target Maintained With a $28.00/Share by Wedbush
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $23 price target.
HC Wainwright & Co. : The Tyra Biosciences (TYRA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $23.00.
HC Wainwright & Co. : The Tyra Biosciences (TYRA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $23.00.
Tyra Biosciences Q1 2024 Adj EPS $(0.35) Beats $(0.46) Estimate
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.46) by 23.91 percent.
TYRA BIOSCIENCES, INC. | 10-Q: Quarterly report
Press Release: Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire CARLSBAD, Calif., May 9, 2024 - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH I
Press Release: Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to Its Board of Directors
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately.
Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Wedbush analyst Robert Driscoll reiterates Tyra Biosciences with a Outperform and maintains $28 price target.
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Raises Price Target to $23
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences with a Buy and raises the price target from $19 to $23.
Tyra Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 42.86% HC Wainwright & Co. $19 → $23 Reiterates Buy → Buy 12/29/2023 67.7% Wedbush $27 → $27 Re
Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
Tyra Biosciences Inc Files For Resale Of Up To 15.4M Shares By The Selling Securityholders
Tyra Biosciences Inc Files For Resale Of Up To 15.4M Shares By The Selling Securityholders
Tyra Biosciences Q4 Net Loss Widens
Tyra Biosciences (TYRA) reported a Q4 net loss late Tuesday of $0.53 per diluted share, compared with a loss of $0.31 per share a year earlier. Analysts polled by Capital IQ expected a loss of $0.48.
Tyra Biosciences GAAP EPS of -$0.53 Misses by $0.05
Tyra Biosciences Files to Sell 15.37M Shares of Common Stock for Holders
Tyra Biosciences: Pro-forma Cash Position of About $403.5 M Expected to Support Clinical and Operational Milestones Through at Least 2026 >TYRA
Tyra Biosciences: Pro-forma Cash Position of About $403.5 M Expected to Support Clinical and Operational Milestones Through at Least 2026 >TYRA
Tyra Biosciences: Advanced SURF301 Phase 1 Oncology Study; Initial Phase 1 Results to Be Reported in 2H >TYRA
Tyra Biosciences: Advanced SURF301 Phase 1 Oncology Study; Initial Phase 1 Results to Be Reported in 2H >TYRA
Analysis
Price Target
No Data
